Triple Marker with Graph (2nd Trimester) near me in Hyderabad
The Triple Marker with Graph (2nd Trimester) test is a prenatal screening test typically conducted between 14-22 weeks of gestation, ideally between 15-20 weeks (the second trimester) of pregnancy, and tells about the risk of specific chromosomal abnormalities, such as Down syndrome (Trisomy 21), Edwards Syndrome (Trisomy 18), neural tube defects (such as spina bifida) and anencephaly (a brain defect) in the fetus.
It measures the levels of three biomarkers in the mother’s blood: Alpha-fetoprotein (AFP), Human chorionic gonadotropin (HCG), and Estriol unconjugated (uE3). The levels of these markers, maternal age, gestational age, and ultrasound findings help determine the likelihood of these chromosomal conditions in the fetus. In addition to the traditional triple marker analysis, including a graphical representation enhances the interpretability of results.
No special preparation is required before undergoing the Triple Marker with Graph (2nd Trimester) test; you can eat or drink as per your daily routine. However, a pregnant woman must provide informed consent before undertaking this test. The laboratory personnel will explain the purpose, benefits, and limitations of this test.
YES (2)
NO (1)
- Conde-Agudelo A, Kafury-Goeta AC. Triple-marker test as screening for Down syndrome: a meta-analysis. 1998. In: Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-. Available from:
- Genetic Alliance; District of Columbia Department of Health. Understanding Genetics: A District of Columbia Guide for Patients and Health Professionals. Washington (DC): Genetic Alliance; 2010 Feb 17. Appendix F, Maternal Serum Marker Screening. Available from:
- Driscoll DA, Gross SJ; Professional Practice Guidelines Committee. Screening for fetal aneuploidy and neural tube defects. Genet Med. 2009 Nov;11(11):818-21. [Accessed 02 May 2024]. Available from:
- Greene ND, Copp AJ. Neural tube defects. Annu Rev Neurosci. 2014;37:221-42. [Accessed 02 May 2024]. Available from:
- Screening for Down's syndrome, Edwards' syndrome and Patau's syndrome [Internet]. NHS; 19 April 2021 [Accessed 02 May 2024]. Available from:
- Sablok A, Sharma A, Ahmed CS, Kaul A. Performance of second-trimester maternal biochemistry screening (quadruple test vs. triple test) for trisomy 21: An Indian experience. Indian J Med Res. 2021 May;154(5):716-722. [Accessed 02 May 2024]. Available from:
- Gordon S, Umandap C, Langaker MD. Prenatal Genetic Screening. [Updated 2023 Jan 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from:
- Commit to Healthy Choices to Help Prevent Birth Defects [Internet]. CDC; 28 June 2023 [Accessed 02 May 2024]. Available from:
- Institute of Medicine (US) Committee on Improving Birth Outcomes; Bale JR, Stoll BJ, Lucas AO, editors. Reducing Birth Defects: Meeting the Challenge in the Developing World. Washington (DC): National Academies Press (US); 2003. 3, Interventions to Reduce the Impact of Birth Defects. [Accessed 02 May 2024]. Available from: